* Please kindly note that our products are not to be used for therapeutic purposes and cannot be sold to patients.
CDK4-R24C (23-32) is a peptide derived from CDK4-R24C. The common mutation in CDK4 (CDK4R24C) in melanoma inhibits the interaction with p16INK4A and thus leads to constitutive activation.